GOVX vs. PHAS, ARDS, NEXI, MBIO, BCEL, SXTP, PHIO, EVOK, ARAV, and RNAZ
Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include PhaseBio Pharmaceuticals (PHAS), Aridis Pharmaceuticals (ARDS), NexImmune (NEXI), Mustang Bio (MBIO), Atreca (BCEL), 60 Degrees Pharmaceuticals (SXTP), Phio Pharmaceuticals (PHIO), Evoke Pharma (EVOK), Aravive (ARAV), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical preparations" industry.
PhaseBio Pharmaceuticals (NASDAQ:PHAS) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
GeoVax Labs has a net margin of 0.00% compared to GeoVax Labs' net margin of -12,572.13%. GeoVax Labs' return on equity of 0.00% beat PhaseBio Pharmaceuticals' return on equity.
49.0% of PhaseBio Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 9.9% of PhaseBio Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
PhaseBio Pharmaceuticals has a beta of 2.57, indicating that its stock price is 157% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 2.89, indicating that its stock price is 189% more volatile than the S&P 500.
GeoVax Labs has lower revenue, but higher earnings than PhaseBio Pharmaceuticals. GeoVax Labs is trading at a lower price-to-earnings ratio than PhaseBio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, PhaseBio Pharmaceuticals' average media sentiment score of 1.14 beat GeoVax Labs' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media.
PhaseBio Pharmaceuticals received 107 more outperform votes than GeoVax Labs when rated by MarketBeat users. However, 91.67% of users gave GeoVax Labs an outperform vote while only 61.78% of users gave PhaseBio Pharmaceuticals an outperform vote.
GeoVax Labs has a consensus price target of $120.00, indicating a potential upside of 7,954.23%.
Summary
PhaseBio Pharmaceuticals and GeoVax Labs tied by winning 7 of the 14 factors compared between the two stocks.
Get GeoVax Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GeoVax Labs Competitors List
Related Companies and Tools
